PGEN$6.944.52%0.30
After Hours: 5.30-1.64 -23.63%
Precigen Inc (PGEN)
Date: 2026-10-30 16:00O: 6.49H: 7.04L: 6.49C: 6.94Vol: 6.822M
Precigen Inc stock is traded at $6.94, with a volume of 6,821,515. It is up +4.52% in the last 24 hours and down -18.93% over the past month. Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Previous Close:
$6.64
Open:
$6.49
24h Volume:
6,821,515
Relative Volume:
1.33
Market Cap:
$2.48B
Revenue:
$9.68M
Net Income/Loss:
-$250.64M
P/E Ratio:
-
EPS:
-$1.40
Net Cash Flow:
-$89.83M
1W Performance:
+12.12%
1M Performance:
-18.93%
6M Performance:
+66.83%
1Y Performance:
+71.36%
1-Day Range:
$6.49$7.04
1-Week Range:
$5.96$7.04
52-Week Range:
$3.04$8.98
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen IncSector
HealthcareIndustry
BiotechnologyPhone
301-556-9900Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, USACompare PGEN vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN Precigen Inc | $6.94 | $2.48B | $9.68M | -$250.64M | -$89.83M | -$1.40 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precigen Inc Stock (PGEN) Insider Trading
- KINDLER JEFFREY BAug 26 '26Director
- Transaction
- Sale
- Cost
- $7.44
- #Shares
- 185,000
- Value ($)
- 1,376,400
- #Shares Total
- 17,100
- Jeffrey KindlerAug 26 '26Director
- Transaction
- Proposed Sale
- Cost
- $7.42
- #Shares
- 185,000
- Value ($)
- 1,372,700
- #Shares Total
- 0
- Tennant PhilAug 25 '26Chief Commercial Officer
- Transaction
- Option Exercise
- Cost
- $1.61
- #Shares
- 79,166
- Value ($)
- 127,457
- #Shares Total
- 221,158
- Tennant PhilAug 25 '26Chief Commercial Officer
- Transaction
- Sale
- Cost
- $7.50
- #Shares
- 79,166
- Value ($)
- 593,745
- #Shares Total
- 141,992
- Shah Rutul RAug 25 '26Officer
- Transaction
- Proposed Sale
- Cost
- $7.50
- #Shares
- 15,342
- Value ($)
- 115,065
- #Shares Total
- 0
- Shah Rutul RAug 25 '26Chief Operating Officer
- Transaction
- Sale
- Cost
- $7.50
- #Shares
- 15,342
- Value ($)
- 115,065
- #Shares Total
- 468,865
- Tennant PhilAug 25 '26Officer
- Transaction
- Proposed Sale
- Cost
- $7.50
- #Shares
- 79,166
- Value ($)
- 593,745
- #Shares Total
- 0
- Shah Rutul RAug 25 '26Chief Operating Officer
- Transaction
- Option Exercise
- Cost
- $2.33
- #Shares
- 15,342
- Value ($)
- 35,747
- #Shares Total
- 484,207
- AGEE NANCY HAug 21 '26Director
- Transaction
- Buy
- Cost
- $7.23
- #Shares
- 3,411
- Value ($)
- 24,662
- #Shares Total
- 309,187
- Shah Rutul RAug 21 '26Chief Operating Officer
- Transaction
- Option Exercise
- Cost
- $2.33
- #Shares
- 34,658
- Value ($)
- 80,753
- #Shares Total
- 499,670
